PBLA (Panbela Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics 3-Year Dividend Growth Rate?

Panbela Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The historical rank and industry rank for Panbela Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

PBLA's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Panbela Therapeutics's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Panbela Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Panbela Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Panbela Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panbela Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's 3-Year Dividend Growth Rate falls into.

Panbela Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Panbela Therapeutics (OTCPK:PBLA) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Panbela Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-1.48
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panbela Therapeutics 3-Year Dividend Growth Rate Related Terms>

Panbela Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387

Website

https://www.panbela.com

Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.

Executives

Jennifer K. Simpson	director, officer: President and CEO	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath	officer: V.P. of Finance & CFO	4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob	director	712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer	director	712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust	10 percent owner	1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson	10 percent owner	130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel	director	712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill	director	712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen	officer: Chief Financial Officer	3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen	director	43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr	director
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen	director	712 VISTA BLVD, #305, WACONIA MN 55387